Pharmacological Interventions for Addressing Pediatric and Adolescent Obesity: A Systematic Review and Network Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2025 Feb 27

PMID 40014613

Authors

Shuo Yang

Shuangqing Xin

Ronghui Ju

Peizhuo Zang

Affiliations

Soon will be listed here.

Abstract

Background: Obesity significantly impacts the health outcomes of children and adolescents, necessitating a comprehensive study to evaluate the effects of various anti-obesity medications (AOMs) on weight-related and metabolic outcomes.

Methods: PubMed, EMBASE, and CENTRAL were searched for studies published up to January 3, 2024. We performed a network meta-analysis on randomized clinical trials that compared various treatments for pediatric and adolescent obesity, such as phentermine/topiramate, semaglutide, exenatide, liraglutide, topiramate, metformin, fluoxetine, metformin/fluoxetine, sibutramine, and orlistat. The study evaluated body mass index (BMI), BMI percentage change, weight, BMI-SDS, waist circumference, metabolic, anthropometric, and safety outcomes.

Results: The study gathered 2733 studies, including 30 articles that involved 3822 participants. The results of our research showed that PHEN/TPM was better at lowering BMI than exenatide, liraglutide, metformin, fluoxetine, Met/Flu, topiramate, orlistat, and sibutramine, with mean differences (MD) ranging from -10.29 to -1.28. Additionally, semaglutide demonstrated superior efficacy over other AOMs (MD ranged from -8.28 to -1.24). Various levels of certainty, ranging from very low to moderate, supported the findings. Furthermore, semaglutide demonstrated superior efficacy over exenatide (MD-12.43, 95% CI -23.95 to -0.30) regarding percentage change in BMI. Semaglutide also showed enhanced weight reduction effectiveness compared to seven other AOMs except for PHEN/TPM (MD ranging from -15.56 to -12.65). Similarly, PHEN/TPM displayed greater weight reduction effectiveness than seven other AOMs, except for semaglutide (MD ranged from -12.17 to -9.27). Moreover, semaglutide proved more effective in decreasing waist circumference when compared with other AOMs apart from PHEN/TPM (MD ranged from -11.61 to -6.07). Similarly, we found that PHEN/TPM, excluding semaglutide and sibutramine, was more effective in reducing waist circumference (MD ranged from -8.64 to -5.51).

Conclusions: The study found that semaglutide outperformed other AOMs in reducing BMI and additional weight-related outcomes in children and adolescents with obesity, while PHEN/TPM showed comparable efficacy.

References

Di Figlia-Peck S, Feinstein R, Fisher M . Treatment of children and adolescents who are overweight or obese. Curr Probl Pediatr Adolesc Health Care. 2020; 50(9):100871. PMC: 7576185. DOI: 10.1016/j.cppeds.2020.100871. View

Weghuber D, Forslund A, Ahlstrom H, Alderborn A, Bergstrom K, Brunner S . A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020; 15(7):e12624. DOI: 10.1111/ijpo.12624. View

de Ferranti S, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly A . Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(13):e603-e634. DOI: 10.1161/CIR.0000000000000618. View

Styne D, Arslanian S, Connor E, Farooqi I, Murad M, Silverstein J . Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102(3):709-757. PMC: 6283429. DOI: 10.1210/jc.2016-2573. View

Fox C, Kelly A, Reilly J, Theis-Mahon N, Raatz S . Current and future state of pharmacological management of pediatric obesity. Int J Obes (Lond). 2024; . DOI: 10.1038/s41366-024-01465-y. View

Kelly A, Bensignor M, Hsia D, Shoemaker A, Shih W, Peterson C . Phentermine/Topiramate for the Treatment of Adolescent Obesity. NEJM Evid. 2023; 1(6). PMC: 10035585. DOI: 10.1056/evidoa2200014. View

Kelly A, Auerbach P, Barrientos-Perez M, Gies I, Hale P, Marcus C . A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020; 382(22):2117-2128. DOI: 10.1056/NEJMoa1916038. View

Nikolakopoulou A, Higgins J, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M . CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020; 17(4):e1003082. PMC: 7122720. DOI: 10.1371/journal.pmed.1003082. View

Bray G, Kim K, Wilding J . Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18(7):715-723. DOI: 10.1111/obr.12551. View

10.

Clarson C, Mahmud F, Baker J, Clark H, McKay W, Schauteet V . Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009; 36(1):141-6. DOI: 10.1007/s12020-009-9196-9. View

11.

Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383-94. DOI: 10.1016/j.jclinepi.2010.04.026. View

12.

Ryan P, Seltzer S, Hayward N, Rodriguez D, Sless R, Hawkes C . Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. J Pediatr. 2021; 236:137-147.e13. DOI: 10.1016/j.jpeds.2021.05.009. View

13.

Yanovski J, Krakoff J, Salaita C, McDuffie J, Kozlosky M, Sebring N . Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011; 60(2):477-85. PMC: 3028347. DOI: 10.2337/db10-1185. View

14.

Rajjo T, Almasri J, Al Nofal A, Farah W, Alsawas M, Ahmed A . The Association of Weight Loss and Cardiometabolic Outcomes in Obese Children: Systematic Review and Meta-regression. J Clin Endocrinol Metab. 2017; 102(3):758-762. DOI: 10.1210/jc.2016-2575. View

15.

Gadde K, Allison D, Ryan D, Peterson C, Troupin B, Schwiers M . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774):1341-52. DOI: 10.1016/S0140-6736(11)60205-5. View

16.

Tronieri J, Wadden T, Walsh O, Berkowitz R, Alamuddin N, Chao A . Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg. Behav Res Ther. 2020; 131:103639. PMC: 7336389. DOI: 10.1016/j.brat.2020.103639. View

17.

Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen O . Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; 387(24):2245-2257. PMC: 9997064. DOI: 10.1056/NEJMoa2208601. View

18.

Chamay Weber C, Gal-Duding C, Maggio A . Family based behavioral treatment in adolescents suffering from obesity: evolution through adulthood. BMC Pediatr. 2024; 24(1):33. PMC: 10777574. DOI: 10.1186/s12887-023-04497-x. View

19.

Hampl S, Hassink S, Skinner A, Armstrong S, Barlow S, Bolling C . Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023; 151(2). DOI: 10.1542/peds.2022-060640. View

20.

Brannsether B, Eide G, Roelants M, Bjerknes R, Juliusson P . BMI and BMI SDS in childhood: annual increments and conditional change. Ann Hum Biol. 2016; 44(1):28-33. DOI: 10.3109/03014460.2016.1151933. View